Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer
{{output}}
Background: This study evaluates the cost-effectiveness of tucatinib plus trastuzumab compared to pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer ... ...
